CFTR and cystic fibrosis: While lumacaftor/ivacaftor diminishes pulmonary exacerbations and risk of hospitalization in CF patients2, when compared to ivacaftor alone (a CFTR modulator of gating mutations)3, lumacaftor/ivacaftor is significantly less effective in improving two key outcomes, lung function and body mass index (BMI).